Juan Sanchez, MD
Pulmonary Disease · Temple, TXNPI 1710996046
Payments from drug & device makers
Across 23 payments — averaging $202.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Olympus Corporation Of The Americas$551
- Medtronic$115
- United Therapeutics Corporation$19
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
- Veran Medical Technologies, Inc.$16
- plus $31 from 3 others
What the payments were for
- Travel & lodging$1,16325%
- Food & beverage$45410%
- Education$3,03265%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $3,899 |
| Olympus Corporation Of The Americas | 6 | $551 |
| Medtronic | 1 | $115 |
| United Therapeutics Corporation | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Veran Medical Technologies, Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Daxor Corporation | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,649 in reported general payments places this provider in the 55th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 27 | $516,986 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 152 | $175,845 |
| OpsumitMacitentan | 11 | $138,988 |
| EsbrietPirfenidone | 12 | $125,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $91,117 |
| NucalaMepolizumab | 24 | $88,532 |
| Dupixent SyringeDupilumab | 12 | $44,087 |
| Atovaquone | 26 | $17,690 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $12,209 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $10,160 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,859 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 170 | $9,298 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $8,618 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,579 |
| Mycophenolate Mofetil | 33 | $4,670 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Temple
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.